Mahamaya Lifesciences Limited, incorporated in 2002, is engaged in providing high-quality Agriculture Crop Protection Solutions through manufacturing and supply of pesticide formulations. It earns revenue from both domestic sales and exports of agrochemicals, supplying to Indian agrochemical firms and multinational corporations (MNCs). The company also imports essential technical molecules not manufactured in India, formulates them domestically, and markets value-added products.

The Company is led by Promoter, i.e., Mr. Krishnamurthy Ganesan, Mrs. Lalitha Krishnamurthy, Mr. Prashant Krishnamurthy

The Revenues from operations for the Period ended on Jun 30, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 8,403.90 Lakhs, ₹  26,717.31 Lakhs, â‚¹  16,282.75 Lakhs, and ₹  13,739.91 Lakhs, The EBITDA for the Period ended on Jun 30, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 803.64 Lakhs, ₹  2,464.44 Lakhs, â‚¹  1,335.84 Lakhs, and ₹ 891.37 Lakhs, The Profit after Tax for the Period ended on Jun 30, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were â‚¹ 410.38 Lakhs, ₹  1,294.32 Lakhs, â‚¹  521.86 Lakhs, and ₹  375.06 Lakhs, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of â‚¹  7.6 and post-issue EPS of ₹ 6.68 for FY25. The pre-issue P/E ratio is  15.00x, while the post-issue P/E ratio is 17.06x against the Industry P/E ratio is 132x. The company's ROE for FY25 is 34.94% and RoNW is 26.19%. The Annualised EPS is ₹  8.48x and P/E is 13.45x. These metrics suggest that the IPO is fully priced.

The Grey Market Premium (GMP) of Mahamaya Lifesciences showing listing gains of 0.00%. Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid to the Mahamaya Lifesciences Limited IPO for Listing gain or Long Term Purposes.